$5.5 Million Boost for Spruce Biosciences as Patient Advocates Fund Rare Disease Therapy — Spruce Biosciences, Inc.

Event summary

$5.5 million strategic investment in Spruce Biosciences from Cure Sanfilippo Foundation and National MPS Society.
Funds will support TA-ERT Expanded Access Program (EAP) for Sanfilippo Syndrome Type B (MPS IIIB).
TA-ERT EAP aims to provide early access to treatment for children with MPS IIIB in the U.S.
Program expected to enroll approximately 10 participants, initiating as early as Q4 2026.

The big picture

The investment underscores the growing collaboration between biopharmaceutical companies and patient advocacy groups to accelerate access to therapies for ultra-rare diseases. Spruce's focus on MPS IIIB, a condition with no FDA-approved treatments, highlights the strategic importance of targeted enzyme replacement therapies in addressing unmet medical needs. The $5.5 million infusion reflects confidence in TA-ERT's potential, but success hinges on navigating regulatory hurdles and demonstrating clinical efficacy.

What we're watching

Regulatory Pathway: Whether Spruce can secure FDA accelerated approval for TA-ERT, given the Breakthrough Therapy Designation and Rare Pediatric Disease Designation.
Execution Risk: The pace at which Spruce can initiate and complete the TA-ERT EAP, with potential challenges in manufacturing and site activation.
Patient Advocacy Impact: How the involvement of Cure Sanfilippo Foundation and National MPS Society will influence regulatory decisions and reimbursement discussions for TA-ERT.